dual specificity CD38 and BCMA CAR-T cell immunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for dual specificity CD38 and BCMA CAR-T cell immunotherapy, covering 2018-12-07 to 2018-12-07. Get the full timeline:
Most recent: Clinical Trial Update: A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]